Amaya Ramírez de Olano, Joaquim Bellmunt, Ana Rodrigo, Luis Álvarez, Adriana Terrádez, Jesús García-Foncillas, Jean-François Laes
Case Rep Oncol. 2017 Jun 9;10(2):493-500. doi: 10.1159/000477337. eCollection 2017 May-Aug.
We present a muscle-invasive high-grade metastatic urothelial carcinoma patient, aged 71 years, with rapid progression from the diagnosis and a poor prognosis after 3 lines of treatment. A clinical exhaustive genomic profile was performed with the goal of finding po- tential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a nonstandard chemotherapy combination treatment identified by the molecular profiling, which would otherwise not have been considered. This approach illustrates the clinical benefit of a comprehensive genomic analysis in an aggressive and re- fractory urothelial carcinoma.